Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

A 29-year-old mother from Australia has opened up about a devastating early-onset Alzheimer’s diagnosis and detailed the ...

Erin Kelly, from Queensland, Australia, recently learned she had the disease after inheriting a rare genetic mutation called ...

Koenraad Köllmann is bicycling from Portland, Oregon to Portland, Maine, in a powerful message to end the stigma.

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...